Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

• Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs
• The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders
• Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of a trained therapist
• The company has been preparing to initiate a Phase 2a clinical trial for the psychedelic candidate in partnership with a medical research team at the University of Florida

The idea of using psychedelic, mind-tripping drugs as pharmaceuticals to help improve the quality of people’s lives no longer seems as far out as it once might have during the heyday of the multinational war on drugs. An increasing cadre of investigational science efforts are utilizing psychedelics to determine their potential in creating better medicine for select conditions with neurological-based maladies.

San Diego-based pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is turning its own investigational machinery toward the development of drug candidates TRP-8802, a synthetic psilocybin formulation being aimed at fibromyalgia and certain eating disorders.

The development of TRP-8802 is taking place under Tryp’s trademarked Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program, which is also evaluating the potential of synthetic psilocybin for treating neuropsychiatric-based chronic pain conditions and eating disorders, such as binge eating and hypothalamic obesity.

The company is partnering with the University of Florida and lead investigator Jennifer Miller, M.D., for a Phase 2a clinical trial looking into TRP-8802’s safety and efficacy in treating eating disorders.

“The research we’re actually going to be doing at the University of Florida with psilocybin is focusing on a little bit more intense problems than just eating disorders,” Dr. Miller said during an interview with The Dales Report published May 3 (https://ibn.fm/F4kho). “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders, primarily something called hyperphagia, where (the patients) just never feel full, so they are constantly wanting to eat.”

Dr. Miller, a professor of pediatrics and endocrinology at the University of Florida, said researchers will look at the efficacy in treating people with uncontrollable eating urges resulting from the genetic disorder PWS, hypothalamic obesity eating disorder resulting from the removal of a brain tumor, and binge eating disorder.

“All of the currently available approved obesity and eating disorder medications are daily medications: you stop taking them, you stop having the efficacy,” Miller said. “Our hope is with psilocybin, … (that) once- or twice-a-year treatments will allow these neural networks to rewire themselves and provide a more chronic treatment, which doesn’t exist right now. … None of the currently available treatments or even past available treatments touch their appetite and fullness.”

Tryp’s ambitions are being fueled by other institutions’ recent studies into psychedelics’ benefits and efforts to open legislative avenues for broader legal use of psychedelics in wellness programs.

Science magazine hailed study results published earlier this month that indicated ecstasy (the compound 3,4-methylenedioxymethamphetamine, or MDMA) alleviated post-traumatic stress disorder (“PTSD”) in a phase 3 clinical trial, branding them a “milestone in efforts to turn psychedelic drugs into mainstream treatments,” particularly because it involved administering a mind-altering drug under the care of a trained therapist (https://ibn.fm/HDaqz).

In the United Kingdom, a recent documentary examined a study by renowned neuropsychopharmacologist David Nutt into uses of psilocybin as a potentially better treatment for depression than commonly prescribed medications (https://ibn.fm/Gcuuy). and researchers at the University of California, Davis report they have achieved a medical breakthrough with their discovery of a psychedelic molecule that doesn’t trigger hallucinations (https://ibn.fm/RLCrm).

In regard to the eating disorders stay at the University of Florida, Tryp President and Chief Science Officer Jim Gilligan, Ph.D. told The Dales Report, “What Tryp is supplying is the psychedelic expertise as a complement … We take luminaries in the field, such as Dr. Miller in eating disorders, and pair with Tryp, and we think that gives us the best likelihood of a positive outcome.”

Gilligan added, “What we’d like to be able to do is, in a way, demystify … and show that, ‘Look, there’s good clinical data’; there’s good reason to believe that there’s an opportunity to do this, and I think the more groups that have success across the spectrum, the better off we’re going to be.”

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.